| abstract |
The present invention relates to 2-methylene-20-methyl-19,24,25,26,27-pentanol-vitamin D analogs, particularly 2-methylene-20-methyl-1α-hydroxy-19,24,25,26, 27-pentanol-vitamin D 3 and its pharmaceutical use are disclosed. The compounds are active in inhibiting the growth of undifferentiated cells and inducing their differentiation into monocytes, and are therefore used as anticancer agents and skin conditions such as wrinkles, sagging skin, dry skin and insufficient sebum secretion. It also proves its use for the treatment of skin diseases like psoriasis. The compounds have little, if any, calcemia activity and can therefore be used for the treatment of human autoimmune disorders or inflammatory diseases as well as renal osteodystrophy. This compound can also be used for the treatment or prevention of obesity. [Selection figure] None |